MA38487A1 - Agents séquestrants de précurseurs de produits terminaux de glycation avancée (age) - Google Patents
Agents séquestrants de précurseurs de produits terminaux de glycation avancée (age)Info
- Publication number
- MA38487A1 MA38487A1 MA38487A MA38487A MA38487A1 MA 38487 A1 MA38487 A1 MA 38487A1 MA 38487 A MA38487 A MA 38487A MA 38487 A MA38487 A MA 38487A MA 38487 A1 MA38487 A1 MA 38487A1
- Authority
- MA
- Morocco
- Prior art keywords
- age
- precursors
- sequestering agents
- agents
- end product
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
- C08F126/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Polymers & Plastics (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792719P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/024436 WO2014150873A1 (en) | 2013-03-15 | 2014-03-12 | Sequestrants of advanced glycation end product (age) precursors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA38487A1 true MA38487A1 (fr) | 2017-12-29 |
Family
ID=50439508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38487A MA38487A1 (fr) | 2013-03-15 | 2014-03-12 | Agents séquestrants de précurseurs de produits terminaux de glycation avancée (age) |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20160024233A1 (enExample) |
| EP (1) | EP2968403A1 (enExample) |
| JP (4) | JP2016512830A (enExample) |
| KR (1) | KR20150130492A (enExample) |
| CN (1) | CN105188718A (enExample) |
| AR (1) | AR095593A1 (enExample) |
| AU (2) | AU2014235500A1 (enExample) |
| BR (1) | BR112015023404A8 (enExample) |
| CA (1) | CA2906501A1 (enExample) |
| CL (1) | CL2015002624A1 (enExample) |
| CR (1) | CR20150545A (enExample) |
| DO (1) | DOP2015000221A (enExample) |
| EA (1) | EA201591733A1 (enExample) |
| HK (1) | HK1220607A1 (enExample) |
| IL (1) | IL241406A0 (enExample) |
| MA (1) | MA38487A1 (enExample) |
| MX (1) | MX2015012843A (enExample) |
| PE (1) | PE20151766A1 (enExample) |
| PH (1) | PH12015502019A1 (enExample) |
| SG (2) | SG11201506413PA (enExample) |
| TN (1) | TN2015000390A1 (enExample) |
| TW (1) | TW201521744A (enExample) |
| UY (1) | UY35441A (enExample) |
| WO (1) | WO2014150873A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41202A (fr) * | 2014-12-18 | 2017-10-24 | Genzyme Corp | Copolymères polydiallymine réticulé pour le traitement du diabète de type 2 |
| BR112020003638A2 (pt) * | 2017-08-31 | 2020-09-01 | Cytosorbents Corporation | redução de produtos finais de glicação avançada a partir de fluidos corporais |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5985938A (en) * | 1997-11-05 | 1999-11-16 | Geltex Pharmaceuticals, Inc. | Method for reducing oxalate |
| ES2637020T3 (es) * | 2001-04-18 | 2017-10-10 | Genzyme Corporation | Uso de polímero de amina para reducir la glucosa sérica |
| AU2003263010A1 (en) * | 2003-09-02 | 2005-04-21 | Genzyme Corporation | Method for reducing vascular inflammation |
| US7459502B2 (en) * | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
| US7385012B2 (en) * | 2003-11-03 | 2008-06-10 | Ilypsa, Inc. | Polyamine polymers |
| JP2007523908A (ja) * | 2004-02-17 | 2007-08-23 | ダイナミス セラピューティクス インコーポレイテッド | フルクトサミン３キナーゼ並びにコラーゲン及びエラスチンの形成 |
| FR2883873B1 (fr) * | 2005-03-31 | 2009-07-10 | Pharmamens Sarl | Inhibiteurs d'age |
| US9181364B2 (en) * | 2010-02-24 | 2015-11-10 | Relypsa, Inc. | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants |
-
2014
- 2014-03-12 CA CA2906501A patent/CA2906501A1/en not_active Abandoned
- 2014-03-12 BR BR112015023404A patent/BR112015023404A8/pt not_active Application Discontinuation
- 2014-03-12 MX MX2015012843A patent/MX2015012843A/es unknown
- 2014-03-12 WO PCT/US2014/024436 patent/WO2014150873A1/en not_active Ceased
- 2014-03-12 JP JP2016501535A patent/JP2016512830A/ja active Pending
- 2014-03-12 AU AU2014235500A patent/AU2014235500A1/en not_active Abandoned
- 2014-03-12 SG SG11201506413PA patent/SG11201506413PA/en unknown
- 2014-03-12 US US14/776,059 patent/US20160024233A1/en not_active Abandoned
- 2014-03-12 SG SG10201707590XA patent/SG10201707590XA/en unknown
- 2014-03-12 KR KR1020157028860A patent/KR20150130492A/ko not_active Withdrawn
- 2014-03-12 CN CN201480026330.6A patent/CN105188718A/zh active Pending
- 2014-03-12 HK HK16108617.8A patent/HK1220607A1/zh unknown
- 2014-03-12 EP EP14715503.0A patent/EP2968403A1/en not_active Withdrawn
- 2014-03-12 PE PE2015001994A patent/PE20151766A1/es unknown
- 2014-03-12 EA EA201591733A patent/EA201591733A1/ru unknown
- 2014-03-12 MA MA38487A patent/MA38487A1/fr unknown
- 2014-03-13 TW TW103108910A patent/TW201521744A/zh unknown
- 2014-03-14 UY UY0001035441A patent/UY35441A/es not_active Application Discontinuation
- 2014-03-17 AR ARP140101218A patent/AR095593A1/es unknown
-
2015
- 2015-09-04 TN TN2015000390A patent/TN2015000390A1/en unknown
- 2015-09-08 DO DO2015000221A patent/DOP2015000221A/es unknown
- 2015-09-09 PH PH12015502019A patent/PH12015502019A1/en unknown
- 2015-09-09 IL IL241406A patent/IL241406A0/en unknown
- 2015-09-11 CL CL2015002624A patent/CL2015002624A1/es unknown
- 2015-10-13 CR CR20150545A patent/CR20150545A/es unknown
-
2017
- 2017-12-14 US US15/842,177 patent/US20180265613A1/en not_active Abandoned
-
2018
- 2018-04-25 JP JP2018083623A patent/JP2018135365A/ja active Pending
-
2019
- 2019-02-22 AU AU2019201259A patent/AU2019201259A1/en not_active Abandoned
- 2019-12-06 JP JP2019220818A patent/JP2020055850A/ja active Pending
-
2021
- 2021-12-17 JP JP2021204770A patent/JP2022037143A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CR20150545A (es) | 2015-12-01 |
| SG11201506413PA (en) | 2015-09-29 |
| EP2968403A1 (en) | 2016-01-20 |
| JP2018135365A (ja) | 2018-08-30 |
| PH12015502019A1 (en) | 2016-01-11 |
| BR112015023404A2 (pt) | 2017-07-18 |
| BR112015023404A8 (pt) | 2019-12-03 |
| CA2906501A1 (en) | 2014-09-25 |
| MX2015012843A (es) | 2016-08-08 |
| AU2014235500A1 (en) | 2015-11-05 |
| US20160024233A1 (en) | 2016-01-28 |
| EA201591733A1 (ru) | 2016-01-29 |
| HK1220607A1 (zh) | 2017-05-12 |
| KR20150130492A (ko) | 2015-11-23 |
| CN105188718A (zh) | 2015-12-23 |
| TN2015000390A1 (en) | 2017-01-03 |
| PE20151766A1 (es) | 2015-12-11 |
| SG10201707590XA (en) | 2017-11-29 |
| TW201521744A (zh) | 2015-06-16 |
| CL2015002624A1 (es) | 2016-03-11 |
| US20180265613A1 (en) | 2018-09-20 |
| DOP2015000221A (es) | 2015-12-15 |
| JP2022037143A (ja) | 2022-03-08 |
| JP2020055850A (ja) | 2020-04-09 |
| AR095593A1 (es) | 2015-10-28 |
| JP2016512830A (ja) | 2016-05-09 |
| IL241406A0 (en) | 2015-11-30 |
| WO2014150873A1 (en) | 2014-09-25 |
| UY35441A (es) | 2014-10-31 |
| AU2019201259A1 (en) | 2019-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN03312A (enExample) | ||
| MA38276B1 (fr) | Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif. | |
| MA33299B1 (fr) | Nouvelle formulation de naproxène | |
| EP2683382A4 (en) | DOSAGE SCHEMES FOR THE TREATMENT OF MORBUS FABRY | |
| MA38399B2 (fr) | Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique | |
| PH12013500145B1 (en) | Agonists of gpr40 | |
| MX2013003635A (es) | Compuestos de n-heteroarilo. | |
| MA40283A (fr) | Aptamères spécifiques du récepteur tlr-4 et leurs utilisations | |
| FR2981934B1 (fr) | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. | |
| MA35674B1 (fr) | Derives de chromone, leur procede de preparation et leurs applications therapeutiques | |
| EP2766012A4 (en) | COMPOSITIONS FOR THE TREATMENT OF KIDNEY DRESS AND METHOD FOR THE PRODUCTION THEREOF | |
| EP2889032A4 (en) | COMPOSITION FOR PREVENTING OR TREATING NURSE DISEASES WITH A PYRAZOLE DERIVATIVE | |
| PH12016500814A1 (en) | Heteroaryl butanoic acid derivatives | |
| MA38349A1 (fr) | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) | |
| WO2015059463A3 (en) | Treatment of beta-catenin related diseases8 | |
| EA201200604A1 (ru) | Фармацевтические субстанции на основе митохондриальноадресованных антиоксидантов | |
| MA38253B1 (fr) | Compositions comprenant de la vortioxétine et du donépézil | |
| FR2981936B1 (fr) | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. | |
| EP2857007A4 (en) | PHARMACEUTICAL COMPOSITION WITH VERBENON DERIVATIVES FOR TREATING OR PREVENTING NEURODEGENATIVE ILLNESSES | |
| UA113975C2 (xx) | Застосування фармацевтичної композиції або добавки, яка містить фосфатидилсерин і куркумін (варіанти) | |
| MA38487A1 (fr) | Agents séquestrants de précurseurs de produits terminaux de glycation avancée (age) | |
| WO2011089576A3 (en) | Novel compositions for reducing abeta 42 production and their use in treating alzheimer's disease (ad) | |
| FR2947729B1 (fr) | Composition pharmaceutique pour le traitement du diabete de type ii par voie trans-muqueuse buccale | |
| MA20150350A1 (fr) | Dérivés isoxazolidine | |
| MA39406A1 (fr) | Promédicament de la 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline |